In an interview, Moderna co-founder Kenneth Chien discussed the future of mRNA technology and Moderna’s positioning, tying the company’s early growth to a high-profile partnership that accelerated momentum for the platform. Chien revisited the deal that helped Moderna scale after working with then-small internal capabilities. While the original partner-focused development plans for multiple mRNA programs did not fully materialize as intended, Chien’s comments underscore how platform partnerships can still reshape investor expectations and funding trajectories—even when specific planned assets diverge from initial scope.